Protara Therapeutics (TARA) Other Accumulated Expenses (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Other Accumulated Expenses of $176000.0 for Q1 2026, down 22.12% year-over-year from $226000.0 in Q1 2025, and down 36.92% quarter-over-quarter from $279000.0 in Q4 2025.
Protara Therapeutics (TARA) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Other Accumulated Expenses for 12 consecutive years, with $176000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 22.12% year-over-year to $176000.0; the TTM figure through Mar 2026 stood at $176000.0 (down 22.12% YoY), while the FY2025 annual figure was $279000.0, up 106.67% from the prior year.
- Other Accumulated Expenses slipped to $176000.0 in Q1 2026 per TARA's latest filing, from $279000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $368000.0 in Q3 2024 and bottomed at $79000.0 in Q1 2022.
- Historically, Other Accumulated Expenses has averaged $192235.3 across 5 years, with a median of $178000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses tumbled 71.99% — and 2024, when it jumped 354.32%.
- Protara Therapeutics' Other Accumulated Expenses stood at $182000.0 in 2022, then fell by 1.1% to $180000.0 in 2023, then retreated by 25.0% to $135000.0 in 2024, then jumped by 106.67% to $279000.0 in 2025, then tumbled by 36.92% to $176000.0 in 2026.
- Business Quant data shows TARA's Other Accumulated Expenses at $176000.0 in Q1 2026, $279000.0 in Q4 2025, and $329000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 531,000.00 |
| Mar 31, 2026 | 176,000.00 |
| Dec 31, 2025 | 279,000.00 |
| Sep 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 226,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Sep 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Mar 31, 2024 | 265,000.00 |
| Dec 31, 2023 | 180,000.00 |
| Sep 30, 2023 | 81,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Dec 31, 2022 | 182,000.00 |
| Sep 30, 2022 | 178,000.00 |
| Jun 30, 2022 | 123,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | 251,000.00 |
| Sep 30, 2021 | 267,000.00 |